{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:53:56Z","timestamp":1792065236280,"version":"4.4.0"},"reference-count":43,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DTS23\/00007"],"award-info":[{"award-number":["DTS23\/00007"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC22\/00042"],"award-info":[{"award-number":["AC22\/00042"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["100005ID4"],"award-info":[{"award-number":["100005ID4"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["AECC INNOVA (INNOV223495CELI)"],"award-info":[{"award-number":["AECC INNOVA (INNOV223495CELI)"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["ERA\u2010NETTRANSCAN\u20103(TRNSC213882FORN)"],"award-info":[{"award-number":["ERA\u2010NETTRANSCAN\u20103(TRNSC213882FORN)"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"'la Caixa' Foundation","doi-asserted-by":"publisher","award":["CaixaImpulse Innovation (CI23\u201030316)"],"award-info":[{"award-number":["CaixaImpulse Innovation (CI23\u201030316)"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"'la Caixa' Foundation","doi-asserted-by":"publisher","award":["the CaixaResearch Validate (CI22\u201000266)"],"award-info":[{"award-number":["the CaixaResearch Validate (CI22\u201000266)"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Molecular Oncology"],"abstract":"<jats:p>\n                    Transcription factors (TFs) are often considered undruggable due to their structural complexity. mRNA technologies can overcome this therapeutic limitation by enabling dynamic protein replacement therapies. Here, we explore the TF activity of LCOR (Ligand\u2010dependent corepressor), which suppresses tumor growth, at least in part by inducing the antigen presentation machinery (APM) in tumor cells and constraining cellular plasticity. These effects facilitate tumor immune recognition and immune\u2010mediated tumor eradication. We used poly \u03b2\u2010(amino esters) (pBAE) nanoparticles (NPs) for local delivery of\n                    <jats:italic>Lcor<\/jats:italic>\n                    mRNA in multiple breast cancer models. pBAE\u2010NPs efficiently encapsulate mRNA and facilitate cellular uptake, achieving optimal endosomal escape, resulting in high transfection efficiency\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    , restoring LCOR function in tumor cells and engaging their APM. In preclinical models, intratumoral delivery of\n                    <jats:italic>Lcor<\/jats:italic>\n                    mRNA reduced tumor growth. Importantly, the combination of\n                    <jats:italic>Lcor<\/jats:italic>\n                    mRNA\u2010loaded RH\u2010pBAE\u2010NPs with anti\u2010PDL1 or anti\u2010CTLA4 immunotherapies eradicated most of the tumors in our preclinical TNBC model. Overall, our nanotherapeutic strategy emerges as an innovative TF\u2010replacement therapy in a lock\u2010in\/wipe\u2010out fashion, leveraging the immunogenic effects of LCOR to eradicate breast cancer tumors when combined with immunotherapy.\n                  <\/jats:p>","DOI":"10.1002\/1878-0261.70344","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:11:01Z","timestamp":1792062661000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reprogramming tumor cells with\n                    <scp>LCOR mRNA<\/scp>\n                    nanotherapy to enhance immunotherapy"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-8063","authenticated-orcid":false,"given":"Gabriel","family":"Serra\u2010Mir","sequence":"first","affiliation":[{"name":"Cancer Research Program Hospital del Mar Research Institute (HMRI)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Haro\u2010Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Institut Qu\u00edmic de Sarri\u00e0 (IQS), Universitat Ramon Llull (URL)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-2340","authenticated-orcid":false,"given":"Sandra","family":"Blasco\u2010Benito","sequence":"additional","affiliation":[{"name":"Cancer Research Program Hospital del Mar Research Institute (HMRI)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cannat\u00e0","sequence":"additional","affiliation":[{"name":"Cancer Research Program Hospital del Mar Research Institute (HMRI)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Palomeque","sequence":"additional","affiliation":[{"name":"Cancer Research Program Hospital del Mar Research Institute (HMRI)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-7663","authenticated-orcid":false,"given":"Anna","family":"L\u00f3pez\u2010Plana","sequence":"additional","affiliation":[{"name":"Cancer Research Program Hospital del Mar Research Institute (HMRI)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sanz\u2010Flores","sequence":"additional","affiliation":[{"name":"Cancer Research Program Hospital del Mar Research Institute (HMRI)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8410-2361","authenticated-orcid":false,"given":"Marc","family":"Sabart\u00e9s","sequence":"additional","affiliation":[{"name":"Institut Qu\u00edmic de Sarri\u00e0 (IQS), Universitat Ramon Llull (URL)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7014-3213","authenticated-orcid":false,"given":"Cristina","family":"Fornaguera","sequence":"additional","affiliation":[{"name":"Institut Qu\u00edmic de Sarri\u00e0 (IQS), Universitat Ramon Llull (URL)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0615-8744","authenticated-orcid":false,"given":"Toni","family":"Celi\u00e0\u2010Terrassa","sequence":"additional","affiliation":[{"name":"Cancer Research Program Hospital del Mar Research Institute (HMRI)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"9","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","article-title":"Advances in targeting \u2018undruggable\u2019 transcription factors with small molecules","volume":"20","author":"Henley MJ","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-28279-8","article-title":"Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy","volume":"13","author":"Xiao Y","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41551-018-0284-0","article-title":"Restoration of tumour\u2010growth suppression in vivo via systemic nanoparticle\u2010mediated delivery of PTEN mRNA","volume":"2","author":"Islam MA","year":"2018","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"e_1_2_11_5_1","first-page":"1","article-title":"mRNA\u2010based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin S","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","article-title":"Long\u2010lasting mRNA\u2010encoded interleukin\u20102 restores CD8+ T\u00a0cell neoantigen immunity in MHC class I\u2010deficient cancers","volume":"42","author":"Beck JD","year":"2024","journal-title":"Cancer Cell"},{"issue":"12","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1007\/s13346-024-01585-y","article-title":"Nucleic acid\u2010loaded poly(beta\u2010aminoester) nanoparticles for cancer nano\u2010immuno therapeutics: the good, the bad, and the future","volume":"14","author":"Maga\u00f1a Rodriguez JR","year":"2024","journal-title":"Drug Deliv Transl Res"},{"issue":"10","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","article-title":"Poly(beta\u2010amino ester)s as gene delivery vehicles: challenges and opportunities","volume":"17","author":"Karlsson J","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"issue":"43","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"29986","DOI":"10.1039\/D3RA05830A","article-title":"Engineering oncogene\u2010targeted anisamide\u2010functionalized pBAE nanoparticles as efficient lung cancer antisense therapies","volume":"13","author":"Fornaguera C","year":"2023","journal-title":"RSC Adv"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jconrel.2024.08.018","article-title":"Stealth mRNA nanovaccines to control lymph node trafficking","volume":"374","author":"Garc\u00eda\u2010Fern\u00e1ndez C","year":"2024","journal-title":"J Control Release"},{"issue":"6","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ncb3533","article-title":"Normal and cancerous mammary stem cells evade interferon\u2010induced constraint through the miR\u2010199a\u2013LCOR axis","volume":"19","author":"Celi\u00e0\u2010Terrassa T","year":"2017","journal-title":"Nat Cell Biol"},{"issue":"3","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s43018-022-00339-4","article-title":"LCOR mediates interferon\u2010independent tumor immunogenicity and responsiveness to immune\u2010checkpoint blockade in triple\u2010negative breast cancer","volume":"3","author":"P\u00e9rez\u2010N\u00fa\u00f1ez I","year":"2022","journal-title":"Nat Cancer"},{"issue":"2","key":"e_1_2_11_13_1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI193153","article-title":"Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer","volume":"136","author":"Palomeque J\u00c1","year":"2026","journal-title":"J Clin Invest"},{"issue":"12","key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger S","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade\u2010Feldman M","year":"2017","journal-title":"Nat Commun"},{"issue":"7669","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel SJ","year":"2017","journal-title":"Nature"},{"issue":"6","key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti\u2010CTLA\u20104 and anti\u2010PD\u20101 checkpoint blockade","volume":"170","author":"Wei SC","year":"2017","journal-title":"Cell"},{"issue":"2","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN\u2010\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti\u2010CTLA\u20104 therapy","volume":"167","author":"Gao J","year":"2016","journal-title":"Cell"},{"issue":"2","key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD\u20101 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin DS","year":"2017","journal-title":"Cancer Discov"},{"issue":"9","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple\u2010negative breast cancer","volume":"382","author":"Schmid P","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien V","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41416-023-02501-w","article-title":"Long\u2010term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early\u2010stage triple\u2010negative breast cancer: an extracted individual patient data and trial\u2010level meta\u2010analysis","volume":"130","author":"Cunha MT","year":"2023","journal-title":"Br J Cancer"},{"key":"e_1_2_11_23_1","first-page":"1","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early\u2010stage triple\u2010negative breast cancer: a phase 2 adaptive trial","volume":"2024","author":"Nederlof I","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1039\/C8ME00006A","article-title":"Stable and efficient generation of poly(\u03b2\u2010amino ester)s for RNAi delivery","volume":"3","author":"Dosta P","year":"2018","journal-title":"Mol Syst Des Eng"},{"issue":"6","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1039\/D2NA00800A","article-title":"Unravelling the role of individual components in pBAE\/polynucleotide polyplexes in the synthesis of tailored carriers for specific applications: on the road to rational formulations","volume":"5","author":"Naval\u00f3n\u2010L\u00f3pez M","year":"2023","journal-title":"Nanoscale Adv"},{"issue":"5","key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.actbio.2013.12.054","article-title":"Oligopeptide\u2010terminated poly(\u03b2\u2010amino ester)s for highly efficient gene delivery and intracellular localization","volume":"10","author":"Segovia N","year":"2014","journal-title":"Acta Biomater"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.actbio.2015.03.029","article-title":"Surface charge tunability as a powerful strategy to control electrostatic interaction for high efficiency silencing, using tailored oligopeptide\u2010modified poly(beta\u2010amino ester)s (PBAEs)","volume":"20","author":"Dosta P","year":"2015","journal-title":"Acta Biomater"},{"issue":"21","key":"e_1_2_11_28_1","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside\u2010modified, protein\u2010encoding mRNA","volume":"39","author":"Karik\u00f3 K","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"26","key":"e_1_2_11_29_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson J","year":"2020","journal-title":"Sci Adv"},{"issue":"19","key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1128\/MCB.25.19.8507-8519.2005","article-title":"Orphan nuclear receptor GCNF is required for the repression of pluripotency genes during retinoic acid\u2010induced embryonic stem cell differentiation","volume":"25","author":"Gu P","year":"2005","journal-title":"Mol Cell Biol"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4939-9450-2_9","article-title":"A SIINFEKL\u2010based system to measure MHC class I antigen presentation efficiency and kinetics","volume":"1988","author":"Dersh D","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"2","key":"e_1_2_11_32_1","article-title":"Repeated PD\u20101\/PD\u2010L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer","volume":"5","author":"Mall C","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"5","key":"e_1_2_11_33_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2022.100632","article-title":"Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights","volume":"3","author":"Shendy NAM","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-23-1510","article-title":"Cell states in cancer: drivers, passengers, and trailers","volume":"14","author":"Gargiulo G","year":"2024","journal-title":"Cancer Discov"},{"issue":"523","key":"e_1_2_11_35_1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1565","article-title":"Synthetic mRNA nanoparticle\u2010mediated restoration of p53 tumor suppressor sensitizes p53\u2010deficient cancers to mTOR inhibition","volume":"11","author":"Kong N","year":"2019","journal-title":"Sci Transl Med"},{"issue":"19","key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1089\/hum.2021.152","article-title":"Preclinical assessment of a gene\u2010editing approach in a mouse model of mitochondrial Neurogastrointestinal Encephalomyopathy","volume":"32","author":"Par\u00e9s M","year":"2021","journal-title":"Hum Gene Ther"},{"issue":"7","key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1021\/acs.nanolett.8b00390","article-title":"Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival","volume":"18","author":"Lopez\u2010Bertoni H","year":"2018","journal-title":"Nano Lett"},{"issue":"1","key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2012.09.020","article-title":"Surface modified poly(\u03b2 amino ester)\u2010containing nanoparticles for plasmid DNA delivery","volume":"164","author":"Fields RJ","year":"2012","journal-title":"J Control Release"},{"issue":"17","key":"e_1_2_11_39_1","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201800335","article-title":"mRNA delivery system for targeting antigen\u2010presenting cells in vivo","volume":"7","author":"Fornaguera C","year":"2018","journal-title":"Adv Healthc Mater"},{"issue":"46","key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1039\/c3cc40718g","article-title":"A bioreducible linear poly(\u03b2\u2010amino ester) for siRNA delivery","volume":"49","author":"Kozielski KL","year":"2013","journal-title":"Chem Commun"},{"issue":"5","key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska K","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"12","key":"e_1_2_11_42_1","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou X","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"9","key":"e_1_2_11_43_1","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1078-0432.CCR-23-1316","article-title":"Platinum\u2010based chemotherapy attenuates the effector response of CD8 T\u00a0cells to concomitant PD\u20101 blockade","volume":"30","author":"Mariniello A","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"e_1_2_11_44_1","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134569","article-title":"Immune cell repertoires in breast cancer patients after adjuvant chemotherapy","volume":"5","author":"Gustafson CE","year":"2020","journal-title":"JCI Insight"}],"container-title":["Molecular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1878-0261.70344","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:11:07Z","timestamp":1792062667000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1878-0261.70344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":43,"alternative-id":["10.1002\/1878-0261.70344"],"URL":"https:\/\/doi.org\/10.1002\/1878-0261.70344","archive":["Portico"],"relation":{},"ISSN":["1574-7891","1878-0261"],"issn-type":[{"value":"1574-7891","type":"print"},{"value":"1878-0261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"2025-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1878-0261.70344"}}